Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Common Variable Immunodeficiency 1Agammaglobulinemia 1

Interventions

Dexamethasone 122daratumumab 70Lenalidomide 69Bortezomib 57pomalidomide 46carfilzomib 42Cyclophosphamide 38Calcium Dobesilate 35Specimen Handling 31Biopsy 29Magnetic Resonance Spectroscopy 26isatuximab 21belantamab mafodotin 20fludarabine 19iberdomide 18talquetamab 17Melphalan 15dexamethasone acetate 14dexamethasone 21-phosphate 14auricularum 14fludarabine phosphate 12elotuzumab 12selinexor 10tocilizumab 9X-Rays 8Nivolumab 8trametinib 7Whole-Body Irradiation 7Sirolimus 7Mycophenolic Acid 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Multiple Myeloma × Hizentra × 90 days × Clear all
NCT07582432 2026-05-12

SIGMA

Grifols Biologicals, LLC

Phase 3 Recruiting
49 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06976476 2026-03-11

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
100 enrolled
Plasma cell

Agammaglobulinemia, Multiple Myeloma, Common Variable Immunodeficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡